Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Optic Neuritis – A Case Report and Literature Review

References

• Hamid SHM, Whittam D, Mutch K. et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088–2094. doi:10.1007/s00415-017-8596-7
   PubMed Web of Science ®Google Scholar
• Hyun JW, Woodhall MR, Kim SH, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88(10):811–817. doi:10.1136/jnnp-2017-315998
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al.; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13(1):279. doi:10.1186/s12974-016-0717-1
   PubMedGoogle Scholar
• Narayan R, Simpson A, Fritsche K, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66–72. doi:10.1016/j.msard.2018.07.025
   PubMed Web of Science ®Google Scholar
• Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184.
   PubMed Web of Science ®Google Scholar
• Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009;66(6):833–842. doi:10.1002/ana.21916
   PubMed Web of Science ®Google Scholar
• de Mol CL, Wong Y, van Pelt ED, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020;26(7):806–814. doi:10.1177/1352458519845112
   PubMed Web of Science ®Google Scholar
• Tajfirouz DA, Bhatti MT, Chen JJ. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis. Curr Neurol Neurosci Rep. 2019;19(12):100. doi:10.1007/s11910-019-1014-z
   PubMed Web of Science ®Google Scholar
• Jurynczyk M, Geraldes R, Probert F, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140(3):617–627. doi:10.1093/brain/aww350
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tan S, Chan TCY, et al. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. Br J Ophthalmol. 2018;102(10):1372–1377. doi:10.1136/bjophthalmol-2017-311177
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134. doi:10.1186/s12974-018-1144-2
   PubMed Web of Science ®Google Scholar
• Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8–15. doi:10.1016/j.ajo.2018.07.020
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mohammad S, Tantsis E, et al.; Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127–137. doi:10.1136/jnnp-2017-316880
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al.; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. doi:10.1186/s12974-016-0718-0
   PubMed Web of Science ®Google Scholar
• Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, et al. Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2016;9(5):436–440. doi:10.1177/1756285616655264
   PubMed Web of Science ®Google Scholar
• Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13(1):83–99. doi:10.1016/S1474-4422(13)70259-X
   PubMed Web of Science ®Google Scholar
• Sotirchos ES, Filippatou A, Fitzgerald KC, et al. Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler. 2020;26(11):1360–1371. doi:10.1177/1352458519864928
   PubMed Web of Science ®Google Scholar
• Neto S, Alvarenga R, Vasconcelos C, et al. Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica. Mult Scler. 2013;19(2):173–178. doi:10.1177/1352458512447597
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Kezuka T, Shikishima K, et al. Working group on diagnostic criteria for refractory optic neuritis based on neuroimmunological perspective. epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology. 2019;126(10):1385–1398. doi:10.1016/j.ophtha.2019.04.042
   PubMed Web of Science ®Google Scholar
• Takano S, Hanabusa A, Yoshikawa Y, et al. Pattern visually evoked potentials in Japanese girl with optic neuritis and seropositive to Anti-myelin Oligodendrocyte Glycoprotein (MOG) Antibody. Front Neurol. 2019;10:1339. doi:10.3389/fneur.2019.01339
   PubMed Web of Science ®Google Scholar
• Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6:e572.
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation. 2019;16(1):134. doi:10.1186/s12974-019-1525-1
   PubMedGoogle Scholar
• Carnero Contentti E, Marrodan M, Correale J. Emerging drugs for the treatment of adult MOG-IgG-associated diseases. Expert Opin Emerg Drugs. 2021;26(2):75–78. doi:10.1080/14728214.2021.1919082
   PubMed Web of Science ®Google Scholar
• Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review. Mult Scler Relat Disord. 2021;48:102696. doi:10.1016/j.msard.2020.102696
   PubMed Web of Science ®Google Scholar